Trabeculectomy with Ologen matrix implant versus trabeculectomy with mitomycin-C in primary open-angle glaucoma

Abstract

Background The purpose of this study was to compare the efficacy and the safety of trabeculectomy augmented with Ologen matrix implant versus mitomycin-C (MMC) in cases with primary open-angle glaucoma (POAG). Patients and methods This retrospective comparative study included patients with POAG who presented to the Ophthalmic Center, Mansoura University, from January 2016 to January 2017. Patients were allocated into two groups: group A patients underwent trabeculectomy with Ologen implant and group B included patients who underwent trabeculectomy with MMC. The primary outcome was the change in the intraocular pressure (IOP), with the recorded complications considered as the secondary outcomes. All the patients were followed up for at least 1 year postoperatively. Results A total of 30 eyes of 17 patients were included in the study. There was no statistically significant difference between the two groups in the baseline demographic or clinical data. The IOP dropped from 43.07±6.23 to 16.03±4.2 mmHg at the twelfth month in group A (P 0.05). Hypotony with thin blebs was statistically higher in the MMC group. Conclusion Trabeculectomy augmented with Ologen implant seems to provide the same efficacy as MMC, with fewer complications in cases with POAG.